As pharmaceutical R&D increasingly relies on interoperability, connectivity and data sharing, the way in which life sciences companies approach IP will have to change
Department of Commerce hits Fujian Jinhua with potentially crippling export ban amid its patent and trade secret battle with Micron. Unlike similar penalty against ZTE, this measure is clearly linked to IP theft accusations.
In taking on the big beasts of Silicon Valley so directly, the USPTO director is gambling that he can change the patent narrative they have helped to create
Clerks hired by Justice Gorsuch have the kind of deep-rooted knowledge that may change minds among critical members of the IP bar
In an exclusive interview with IAM, Corey Salsberg sung the praises of the Pat-INFORMED database and predicted more to come for the platform
Just months after Federal Circuit came down hard on RPX, Board's institution of a Unified review petition offers further guidance on determining real-party-in-interest
Stake in mining giant would shore up China’s position in the battery tech supply chain. But top shareholder tells Chile’s highest court that the investment could result in loss of trade secrets.
With big ADR push behind it, office asks firms to weigh in on whether courts provide sufficient IP protection. Commissioner Naoko Munakata previewed the initiative in recent remarks at IPBC Japan.
Heightened concern over pay-for-delay strategies has driven the legislation at a time when the number of biosimilars being approved is set to rise sharply
Six licensing principles have been made public by a group including Nokia, Ericsson and Qualcomm following work done with European standards organisations CEN and CENELEC
On the face of it, the rise in annual filings by Chinese entities was the lowest since 1995 last year; but that may not be the full story. CNIPA points to a change in counting methodology, which only raises more questions.
Senator homes in on divergent views between key agencies on FRAND licensing and risks to development of key technologies
The recently-struck deal promises to boost IP protection for pharma innovators in North America, but it will be years until it has an impact
A state media article blasts ‘fast food-style innovation’ as abandonments data paints a bleak picture.
After eight tumultuous years, Benoît Battistelli is no longer president of the EPO. In June, he sat down with IAM to look back on his controversial tenure. One thing was clear: he would do it the same way all over again